Which alprostadil patents matter most (and what are they protecting)?
Alprostadil is an established drug used for conditions such as erectile dysfunction (in injectable and intraurethral forms) and pulmonary arterial hypertension in specialized formulations. Patent coverage around alprostadil typically falls into a few buckets: (1) the original active-ingredient inventions, (2) specific formulations (for example, intraurethral vs. injectable formats), (3) delivery devices or administration methods, and (4) later “improvement” patents that can extend protection for particular products even after earlier patents expire. The exact patents that matter depend on the specific product and route of administration in your market.
How long do alprostadil patents last, and when do they expire?
Patent term generally follows filing and jurisdiction rules (often 20 years from the earliest effective filing date, with possible extensions depending on the country). In practice, users usually ask “when does it expire?” because that date affects when generic or biosimilar-style competition can appear and when exclusivity ends. For alprostadil, expiration timing is product- and country-specific because different patents (and sometimes different extensions) cover different aspects of the drug/product.
Can generics be made before all alprostadil patents expire?
Often, yes. Even if some patents remain active, others may have expired or may not block generic manufacture/sale. Also, regulatory pathways differ by drug type and jurisdiction. The practical question is which patents are listed/active for the exact dosage form and indication, and whether a generic can “design around” protected aspects such as a formulation, a device, or a method of use.
Are there “method of use” or formulation patents for alprostadil that block competition?
Yes. Even when the chemical entity is older, patents can cover:
- A specific dosage form (such as how the drug is prepared, stabilized, or delivered)
- A specific route (injectable vs. intraurethral)
- A method of administration or clinical regimen for an indication
These kinds of patents can limit what a competitor can sell without licensing, despite other patents expiring.
Why do patent disputes sometimes happen around established drugs like alprostadil?
Because manufacturers may disagree on whether a given patent is valid and enforceable, and whether a competitor’s product infringes. Litigation typically focuses on claim interpretation (what the patent actually covers) and on design-around options. For older drugs, these disputes are common when a company wants market entry but faces an active patent wall.
How do I find the exact alprostadil patent numbers for a specific product or country?
To identify “the” relevant patents, you need:
- The product name (brand name and whether it is intraurethral, injectable, etc.)
- The country/market you care about
- The dosage strength and manufacturer (because patent listings can be product-specific)
Then you can search by active ingredient + product name in that jurisdiction’s patent databases and (in some countries) regulatory patent lists.
What info would help me pinpoint the patents you mean?
If you tell me:
- the country (e.g., US, EP, UK, India, Canada),
- the formulation/route (injectable vs. intraurethral),
- and the brand/product (if you know it),
I can narrow down which patents are likely protecting that specific alprostadil product and how expiration timing typically works for those patent classes.
Sources
I don’t have any patent database links or specific alprostadil patent numbers in the information provided here, so I can’t cite or list exact patents/expiry dates yet. If you share the country and product name, I can respond with a targeted list of relevant patents and their status based on publicly indexed records.